You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK)續漲近7%曾見4.89元 獲委託產改善新冠肺炎症狀中藥製劑
阿思達克 02-10 10:03
中國中藥(00570.HK)獲委託生產改善新冠肺炎症狀中藥製劑,該股六連漲,今早升破上月所創高位4.46元,最多急漲15%高見4.89元,創近十個月高,現造4.53元,續漲6.8%,成交增至6,107萬股,涉資2.84億元。 該公司公布,廣州市第八人民醫院的醫院中藥製劑透解祛瘟顆粒通過廣東省醫療機構傳統中藥製劑應急審批備案,並委託公司旗下子公司廣東一方進行生產配製。公司指,該透解祛瘟顆粒能夠明顯改善新型冠狀病毒感染肺炎(輕症)臨床症狀,有減少重型肺炎發生趨勢,具有較好臨床價值。(sz/t)~ 阿思達克財經新聞 網址: www.aastocks.com
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account